Lonza Group Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	3yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Lonza Group no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Philippe Deecke	Chief Financial Officer	2.5yrs	sin datos	0.0032% CHF 1.3m
Maria Nunez	Head of Group Operations	1.8yrs	sin datos	0.00019% CHF 73.9k
Dirk Oehlers	Vice President of Investor Relations	no data	sin datos	sin datos
Andreas Bohrer	Group General Counsel & Company Secretary	no data	sin datos	sin datos
Kim Harrelson	Head of Ethics & Compliance	no data	sin datos	sin datos
Victoria Morgan	Head of External Communications	no data	sin datos	sin datos
Jennifer Clancy	Senior Director of Global Marketing	6.2yrs	sin datos	sin datos
Ulrike Kaeppler	Chief Human Resources Officer	less than a year	sin datos	sin datos
Matthias Hofmann	Head of Corporate Environment	no data	sin datos	sin datos
Jean-Christophe Hyvert	President of Biologics Division	3.4yrs	sin datos	0.0029% CHF 1.1m
Aurelie Dalbiez	Head of Strategic HR Projects	no data	sin datos	sin datos
Gordon Bates	President of Small Molecules Division	3.4yrs	sin datos	0.0033% CHF 1.3m

3.0yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LZAG.Y se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Barbara Richmond	Independent Non-Executive Director	10.2yrs	CHF316.30k	0.0058% CHF 2.2m
Christoph Mader	Independent Vice Chairman & Lead Independent Director	8.2yrs	CHF334.77k	0.0060% CHF 2.3m
Jurgen Steinemann	Independent Director	10.2yrs	CHF239.33k	0.013% CHF 5.0m
Roger Nitsch	Independent Director	2.1yrs	CHF251.00k	0.00051% CHF 198.5k
Marion Helmes	Independent Director	2.1yrs	CHF239.33k	0.00051% CHF 198.5k
Angelica Kohlmann	Independent Director	6.1yrs	CHF334.77k	0.0023% CHF 887.2k
Olivier Verscheure	Independent Director	6.1yrs	CHF251.00k	0.0021% CHF 817.2k
Jean-Marc Huet	Independent Chairman	less than a year	sin datos	sin datos

6.1yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de LZAG.Y se considera experimentada (6.1 años de antigüedad promedio).

Lonza Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Lonza Group AG Announces Chief Executive Officer Changes

Lonza Group AG, Annual General Meeting, May 08, 2024

Lonza Group AG Announces CEO Changes

Lonza Group AG, Annual General Meeting, May 05, 2023

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022

Lonza Group Announces Management Changes, Effective August 1, 2022

Recent updates

Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024

Lonza Group AG Announces Chief Executive Officer Changes

Lonza Group AG to Report First Half, 2024 Results on Jul 25, 2024

Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024

Lonza Group AG, Annual General Meeting, May 08, 2024

Lonza Group AG Provides Sales Guidance for the Year 2023

Lonza Group AG Announces CEO Changes

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG Reiterates Sales Guidance for the Years 2023

Lonza Group AG to Report First Half, 2023 Results on Jul 21, 2023

Lonza Group AG Provides Earnings Guidance for the Year 2023

Lonza Group AG (SWX:LONN) announces an Equity Buyback for CHF 2,000 million worth of its shares.

Lonza Group AG, Annual General Meeting, May 05, 2023

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022

Lonza Group AG Reconfirms Sales Guidance for the Years 2022 and 2024

Lonza Group Announces Management Changes, Effective August 1, 2022

Sigma-Aldrich Corporation acquired Modular Automated Sampling Technology Platform of Lonza Group AG.

Lonza Group Ltd. Announces Sales Guidance for the Full-Year 2022

Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

Lonza Group Ltd Provides Earnings Guidance for the Year 2021

Lonza Group Ltd Approves Dividend, Payable Starting from May 12, 2021

Altimmune, Inc. Expands AdCOVID™ Manufacturing Collaboration with Lonza

NextPharma Technologies Holding Limited signed an agreement to acquire Lonza's Ploermel (FR) and Edinburgh (UK) sites from Lonza Group Ltd (SWX:LONN).

Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

Aurinia Pharmaceuticals Inc. and Lonza Group Ltd Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

Lonza Group Ltd Announces Management Changes

Lonza Reportedly Starts Disposal of Specialty Ingredients Unit

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad